The aims of this study are two-fold: to investigate the impact of anti-PD1 inhibitors on overall survival in metastatic melanoma, and to describe the cutaneous adverse reactions to anti-PD1 inhibitors in Singapore melanoma patients and their effect on overall survival. The gene discussed is PDCD1; the disease is melanoma.